Clinical experience with autologous tumor cell lines for patient- specific vaccine therapy in metastatic melanoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 13, Issue 3, 1998, Pages 165-176

  Dillman, Robert O ^a   Nayak, Shankar K ^a   Barth, Neil M ^a   Deleon, Cristina ^a   Schwartzberg, Lee S ^b   Spitler, Lynn E ^c   Church, Curtis ^d   O'Connor, Audrey A ^a   Beutel, Linda D ^a  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^b West Clinic   (United States)

^c Jenner Technologies   (United States)

^d Cancer Biotherapy Research Group   (United States)

Author keywords

Cell lines; Melanoma; Tumor vaccine

Indexed keywords

ADJUVANT; ANTIGEN; BCG VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PERIMMUNE; TUMOR VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOGENETICS; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; SEROCONVERSION; SKIN TEST; STATISTICAL ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT INDICATION; TUMOR CELL LINE; VACCINATION;

EID: 0031824962     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1998.13.165     Document Type: Article

References (20)

1. Hersey P. Examination of the scientific basis for vaccines in treatment of melanoma. Vaccine Res 1992; 1:357-372.
2. Morton DL, Foshag LJ, Hoon DSB, Nizze JA, Wanek LA, Chang C, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463-482.
3. Mitchell MS, Harel W, Kempf R A, Hu E, Kan-Mitchell J, Boswell WD, et al. Active-specific immunotherapy for melanoma. J Clin Oncol 1990; 8.856-869.
4. Berd D, Maguire HC Jr, McCue P, Mastrangelo MJ Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J Clin Oncol 1990;8:1858-1867.
5. Miller K, Abeles G, Oratz R, Zeleniuch-Jacquotte A, Cui J, Roses DF, et al. Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. 1995;15:495-502.
6. McGee MC, Lytle GH, Malnar KF, Price JA, Humphrey LJ. Melanoma tumor vaccine: five-year follow-up. J Surg Oncol 1991;47:233-238.
7. Livingston PO, Wong GYC, Adluri S, Tao Y, Padavan M, Parente R, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-1044.
8. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, et al. A phase III randomized, double-blind, multi-institutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995; 75:34-42.
9. McCaffery M, Yao T-J, Williams L, Livingston PO, Houghton AN, Chapman P. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin Cancer Res 1996;2:679-686.
10. Dillman RO, Nayak SK, Beutel L. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother 1993; 14:65-69.
11. Nayak SK, Johnson DE, Prather K, Ramonda L, Dillman RO. Growth of human cancers in tissue culture & athymic mice. Proc Am Assoc Cancer Res 1988; 29-204 (abstr-1610)
12. Nayak SK, Dillman RO. Establishment of multiple tumor cell lines from a patient with melanoma: a simple method to control fibroblast growth. 1991; 3:237-242.
13. Berd D, Murphy G, Maguire HC Jr, Mastrangelo MJ. Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res 1991;51:2731-2734.
14. Barth A, Hoon DSB, Foshag LJ, Nizze JA, Famatiga E, Okun E, Morton DL. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 1994; 54:3342-3345.
15. Bystryn J-C, Oratz R, Roses D, Harris M, Henn M, Lew R. Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 1992;69:157-1164.
16. Dillman R O. Why event-free survival is better than tumor response or other measures of survival as an endpoint in cancer trials. Cancer Biother 1996; 11: 99-104.
17. Dillman RO, Church C, Oldham RK, West WH, Schwartzberg L, Birch R Inpatient continuous infusion interleukin-2 in 788 patients with cancer: the National Biotherapy Study Group experience Cancer 1993; 71:2358-2370.
18. Anderson CM, Buzaid AC, Legha SS Systemic treatments for advanced cutaneous melanoma. Oncol 1995; 9:1149-1158.
19. Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma J Clin Oncol 1996;14:2083-2090.
20. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. : Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996;14:7-17.